We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Sarepta Therapeutics, Inc. (SRPT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 124.45 |
| Open | 124.00 |
| Bid | 122.79 x 200 |
| Ask | 122.97 x 100 |
| Day's Range | 121.49 - 124.82 |
| 52 Week Range | 55.25 - 159.89 |
| Volume | |
| Avg. Volume | 898,775 |
| Market Cap | 11.532B |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.80 |
| Earnings Date | Apr 30, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 165.94 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SRPT
Related Research
- Sarepta Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 11/07/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 months agoArgus Research
Insider Monkey10 Unstoppable Stocks That Will Make You Richer
In this article, we discuss the 10 unstoppable stocks that will make you richer. To skip the detailed analysis of the economy and market, go directly to the 5 Unstoppable Stocks That Will Make You Richer. On April 12, the week closed out with stocks tumbling as the S&P 500 recorded its worst day since […]
Investor's Business DailyWhy Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
Sarepta will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has taken a beating since its last report.
Motley Fool2 Biotech Stocks to Buy Hand Over Fist in April
These drugmakers have made important moves over the past year.
MarketWatchOutperforming ETF manager names a potential ‘50-bagger’ in the stock market
Michael Taylor runs the Simplify Health Care ETF, which donates its management fees to Susan G. Komen for the Cure to fund breast-cancer research and help people with the disease.
Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 29, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in March 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
ZacksSarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Simply Wall St.Sarepta Therapeutics' (NASDAQ:SRPT) growing losses don't faze investors as the stock increases 3.6% this past week
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...
GuruFocus.comA Comprehensive Look at Sarepta's Growth and Innovation
One of the leaders in the global DMD drugs market is expected to outperform
Insider Monkey30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
Insider MonkeyBillionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks
In this article, we will take a detailed look at Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ken Fisher and Corporate Insiders Are Buying These 5 Stocks. Stocks wobbled on Thursday after a hotter-than-expected PPI report confirmed fears that inflation […]
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BLUE bluebird bio, Inc. | |||
| BMRN BioMarin Pharmaceutical Inc. | |||
| ACAD ACADIA Pharmaceuticals Inc. | |||
| ALNY Alnylam Pharmaceuticals, Inc. | |||
| IONS Ionis Pharmaceuticals, Inc. |
Similar to SRPT
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | |||
| BMRN BioMarin Pharmaceutical Inc. | |||
| MDGL Madrigal Pharmaceuticals, Inc. | |||
| INCY Incyte Corporation | |||
| AGIO Agios Pharmaceuticals, Inc. |
Analyst Price Targets (19)
Upgrades & Downgrades
| Maintains | UBS: Buy to Buy | 3/1/2024 | |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 2/29/2024 | |
| Maintains | RBC Capital: Outperform to Outperform | 2/29/2024 | |
| Maintains | Citigroup: Buy to Buy | 2/29/2024 | |
| Maintains | Barclays: Overweight to Overweight | 2/29/2024 | |
| Maintains | Needham: Buy to Buy | 2/29/2024 |
Company Profile
215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,314
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
